Impact of Mean Platelet Volume on Combined Safety Endpoint and Vascular and Bleeding Complications following Percutaneous Transfemoral Transcatheter Aortic Valve Implantation
Table 2
(a) Combined safety endpoint in TAVI patients, univariate analysis, and multivariate analysis. (b) Major vascular complications in TAVI patients, univariate analysis, and multivariate analysis. (c) Life-threatening bleeding events in TAVI patients, univariate analysis, and multivariate analysis.
(a)
Variable
Univariable P value
Multivariable odds ratio (95% CI)
P value
Logistic Euroscore
0.004
1.02 (1.01–1.04)
0.002
Chronic kidney disease
0.014
MPV (fL)
0.016
0.77 (0.62–0.97)
0.024
RDW (%)
0.004
(b)
Variable
Univariable P value
Multivariable odds ratio (95% CI)
P value
Female gender
0.045
2.54 (1.26–5.14)
0.009
Previous MI
0.005
3.25 (1.56–6.76)
0.002
BSA (m2)
0.031
Sheath size (Fr)
0.038
MPV (fL)
0.014
0.7 (0.50–0.96)
0.028
RDW (%)
0.027
1.16 (1.01–1.32)
0.035
(c)
Variable
Univariable P value
Multivariable odds ratio (95% CI)
P value
Peripheral arterial disease
0.008
2.40 (1.25–4.59)
0.008
BSA (m2)
0.053
Logistic Euroscore
0.026
Aortic annulus diameter (mm)
0.024
MPV (fL)
0.015
0.76 (0.58–1.00)
0.05
RDW (%)
0.004
1.15 (1.01–1.32)
0.036
BSA: body surface area; CSEP: combined safety endpoint; MI: myocardial infarction; MPV: mean platelet volume; PCI: percutaneous coronary intervention; RDW: red blood cell distribution width; VASC: vascular complications.
